Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect
Open Access
- 26 April 2005
- journal article
- research article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 172 (9), 1187-1194
- https://doi.org/10.1503/cmaj.1041403
Abstract
Background: Clinical trials have shown the benefits of statins after acute myocardial infarction (AMI). However, it is unclear whether different statins exert a similar effect in reducing the incidence of recurrent AMI and death when used in clinical practice. Methods: We conducted a retrospective cohort study (1997–2002) to compare 5 statins using data from medical administrative databases in 3 provinces (Quebec, Ontario and British Columbia). We included patients aged 65 years and over who were discharged alive after their first AMI-related hospital stay and who began statin treatment within 90 days after discharge. The primary end point was the combined outcome of recurrent AMI or death from any cause. The secondary end point was death from any cause. Adjusted hazard ratios (HRs) for each statin compared with atorvastatin as the reference drug were estimated using Cox proportional hazards regression analysis. Results: A total of 18 637 patients were prescribed atorvastatin (n = 6420), pravastatin (n = 4480), simvastatin (n = 5518), lovastatin (n = 1736) or fluvastatin (n = 483). Users of different statins showed similar baseline characteristics and patterns of statin use. The adjusted HRs (and 95% confidence intervals) for the combined outcome of AMI or death showed that each statin had similar effects when compared with atorvastatin: pravastatin 1.00 (0.90–1.11), simvastatin 1.01 (0.91–1.12), lovastatin 1.09 (0.95–1.24) and fluvastatin 1.01 (0.80–1.27). The results did not change when death alone was the end point, nor did they change after adjustment for initial daily dose or after censoring of patients who switched or stopped the initial statin treatment. Interpretation: Our results suggest that, under current usage, statins are equally effective for secocondary prevention in elderly patients after AMI.Keywords
This publication has 46 references indexed in Scilit:
- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ, 2003
- Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trialCurrent Medical Research and Opinion, 2003
- Physicians’ interpretation of “class effects”: A need for thoughtful re-evaluationJournal of the American College of Cardiology, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease PreventionCurrent Medical Research and Opinion, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of diseaseThe Lancet, 1994